Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

17.30USD
20 Apr 2018
Change (% chg)

$0.10 (+0.58%)
Prev Close
$17.20
Open
$17.10
Day's High
$17.55
Day's Low
$17.10
Volume
53,724
Avg. Vol
89,702
52-wk High
$18.75
52-wk Low
$7.30

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics Says Start Of Rolling BLA Submission For SL-401
Thursday, 5 Apr 2018 07:00am EDT 

April 5 (Reuters) - Stemline Therapeutics Inc ::START OF ROLLING BLA SUBMISSION FOR SL-401.  Full Article

Stemline Therapeutics Inc - Co Launched An At-Market Offering Of Up To $50 Million Worth Of Shares
Friday, 16 Mar 2018 05:29pm EDT 

March 16 (Reuters) - Stemline Therapeutics Inc ::STEMLINE THERAPEUTICS INC - ‍ON MARCH 16, 2018, CO LAUNCHED AN AT--MARKET OFFERING OF UP TO $50 MILLION WORTH OF SHARES OF COMPANY'S COMMON STOCK​.  Full Article

Stemline Therapeutics Q4 Loss Per Share $0.93
Friday, 16 Mar 2018 07:30am EDT 

March 16 (Reuters) - Stemline Therapeutics Inc ::STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.93.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.‍ENDED Q4 OF 2017 WITH $66.2 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS​.  Full Article

Stemline Therapeutics Prices $51.8 Mln Public Offering
Wednesday, 24 Jan 2018 07:00am EST 

Jan 24 (Reuters) - Stemline Therapeutics Inc ::STEMLINE THERAPEUTICS PRICES $51.8 MILLION PUBLIC OFFERING OF COMMON STOCK.STEMLINE THERAPEUTICS INC - ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 3.7 MILLION SHARES OF COMMON STOCK AT A PRICE OF $14.00 PER SHARE​.  Full Article

Stemline Therapeutics Announces Proposed Public Offering Of Common Stock
Monday, 22 Jan 2018 04:01pm EST 

Jan 22 (Reuters) - Stemline Therapeutics Inc ::STEMLINE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.STEMLINE THERAPEUTICS SAYS IT INTENDS TO OFFER AND SELL 3.7 MILLION SHARES OF ITS COMMON STOCK IN A PUBLIC OFFERING.  Full Article

Stemline Therapeutics reports Q3 loss per share $0.68
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.68.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Stemline Therapeutics-‍stemline ended Q3 of 2017 with $79.9 million in cash, cash equivalents and investments, as compared to $93.2 million as of June 30, 2017​.  Full Article

Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​.Stemline Therapeutics Inc - ‍based on feedback from U.S. FDA, co remains on track to begin submission of BLA in 4Q17-1Q18 timeframe for SL-401​.  Full Article

Stemline Therapeutics files for mixed shelf offering of up to $175 mln
Tuesday, 8 Aug 2017 05:44pm EDT 

Aug 8 (Reuters) - Stemline Therapeutics Inc ::Stemline Therapeutics Inc files for mixed shelf offering of up to $175 million - SEC filing‍​.  Full Article

Stemline Therapeutics Q2 loss per share $0.66
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.66.Q2 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial
Thursday, 18 May 2017 07:30am EDT 

May 18 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting.  Full Article

Stemline Therapeutics wins dismissal of shareholder lawsuit

A federal judge has dismissed a lawsuit accusing Stemline Therapeutics Inc of misleading investors about its ability to address the risk of a fatal side effect associated with a drug it was developing to treat certain blood-related cancers.